Longeveron Inc. (LGVN): Total Assets
$10.26M
As of 2025-12-31
$15.49M
As of 2026-06-30
-27.9%
3-year compound annual growth
+2.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.26M | -59.9% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $25.56M | +111.6% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $12.08M | -55.9% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $27.41M | -35.9% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $42.77M | +362.8% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $9.24M | n/a | 2022-03-11, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Longeveron Inc. (LGVN) | 2025-12-31 | $10.26M | -59.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $28.71M | +0.4% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $34.75M | +60.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $48.56M | -42.4% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $8.75M | -11.7% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $359.1K | +1.3% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $7.02M | -35.2% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $81.29M | +204.1% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $32.47M | +46.9% |
Compare LGVN, NEUP, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗